Haque, Md Rafiul
Caraway distillate ameliorate hyperlipidemia and hepatic steatosis in obese rat - Vol.15(4), Oct-Dec - M P BRNSS Publication Hub. 2021 - 406-412p.
Background: Carum carvi L. (family; Apiaceae, common name; caraway) is conventionally used for the
treatment of flatulence, dyspepsia, fatness, asthma, and amenorrhea in Unani as well as the Ayurvedic System
of Indian Medicine. Aim and Objective: The present study was planned to scrutinize the effect of caraway
distillate (CD) on hyperlipidemia and hepatic steatosis in a rat model of high-fat diet (HFD)-induced obesity.
Materials and Methods: HFD-fed rats were administered with CD (7.75 ml/kg body weight [BW] twice a
day, orally) and CD1 (7.75 ml/kg BW once a day, orally) for 4 weeks. Results: After termination of the study,
CD and CD1 treatments showed significant (P < 0.001) attenuation in cholesterol, triglycerides, low-density
lipoprotein cholesterol, leptin levels, and pancreatic lipase activity and significant (P < 0.001) boost in highdensity
lipoprotein cholesterol. Furthermore, CD and CD1 treatment also noticeably attenuated the extent of
hepatic steatosis. Conclusions: These results suggest that CD has a strong protective effect against hyperlipidemia
and hepatic steatosis in HFD-induced obesity on a rat model.
PHARMACOGNOSY
Caraway distillate ameliorate hyperlipidemia and hepatic steatosis in obese rat - Vol.15(4), Oct-Dec - M P BRNSS Publication Hub. 2021 - 406-412p.
Background: Carum carvi L. (family; Apiaceae, common name; caraway) is conventionally used for the
treatment of flatulence, dyspepsia, fatness, asthma, and amenorrhea in Unani as well as the Ayurvedic System
of Indian Medicine. Aim and Objective: The present study was planned to scrutinize the effect of caraway
distillate (CD) on hyperlipidemia and hepatic steatosis in a rat model of high-fat diet (HFD)-induced obesity.
Materials and Methods: HFD-fed rats were administered with CD (7.75 ml/kg body weight [BW] twice a
day, orally) and CD1 (7.75 ml/kg BW once a day, orally) for 4 weeks. Results: After termination of the study,
CD and CD1 treatments showed significant (P < 0.001) attenuation in cholesterol, triglycerides, low-density
lipoprotein cholesterol, leptin levels, and pancreatic lipase activity and significant (P < 0.001) boost in highdensity
lipoprotein cholesterol. Furthermore, CD and CD1 treatment also noticeably attenuated the extent of
hepatic steatosis. Conclusions: These results suggest that CD has a strong protective effect against hyperlipidemia
and hepatic steatosis in HFD-induced obesity on a rat model.
PHARMACOGNOSY